CN101454327A - 作为大麻素1活性抑制剂的吡咯并嘧啶类化合物 - Google Patents

作为大麻素1活性抑制剂的吡咯并嘧啶类化合物 Download PDF

Info

Publication number
CN101454327A
CN101454327A CNA2007800198186A CN200780019818A CN101454327A CN 101454327 A CN101454327 A CN 101454327A CN A2007800198186 A CNA2007800198186 A CN A2007800198186A CN 200780019818 A CN200780019818 A CN 200780019818A CN 101454327 A CN101454327 A CN 101454327A
Authority
CN
China
Prior art keywords
phenyl
dihydro
chloro
pyrimidin
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800198186A
Other languages
English (en)
Chinese (zh)
Inventor
贺晓晖
杨鲲泳
刘宏
D·A·埃里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of CN101454327A publication Critical patent/CN101454327A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
CNA2007800198186A 2006-03-30 2007-03-30 作为大麻素1活性抑制剂的吡咯并嘧啶类化合物 Pending CN101454327A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78831006P 2006-03-30 2006-03-30
US60/788,310 2006-03-30

Publications (1)

Publication Number Publication Date
CN101454327A true CN101454327A (zh) 2009-06-10

Family

ID=38294112

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800198186A Pending CN101454327A (zh) 2006-03-30 2007-03-30 作为大麻素1活性抑制剂的吡咯并嘧啶类化合物

Country Status (21)

Country Link
US (1) US8722691B2 (cg-RX-API-DMAC7.html)
EP (1) EP1999132B1 (cg-RX-API-DMAC7.html)
JP (1) JP5253374B2 (cg-RX-API-DMAC7.html)
KR (1) KR100997601B1 (cg-RX-API-DMAC7.html)
CN (1) CN101454327A (cg-RX-API-DMAC7.html)
AU (1) AU2007239033B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710107A2 (cg-RX-API-DMAC7.html)
CA (1) CA2645967C (cg-RX-API-DMAC7.html)
CR (1) CR10309A (cg-RX-API-DMAC7.html)
EC (1) ECSP088852A (cg-RX-API-DMAC7.html)
ES (1) ES2388881T3 (cg-RX-API-DMAC7.html)
GT (1) GT200800198A (cg-RX-API-DMAC7.html)
MA (1) MA30339B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008012400A (cg-RX-API-DMAC7.html)
NO (1) NO20084489L (cg-RX-API-DMAC7.html)
PL (1) PL1999132T3 (cg-RX-API-DMAC7.html)
PT (1) PT1999132E (cg-RX-API-DMAC7.html)
RU (1) RU2424242C2 (cg-RX-API-DMAC7.html)
TN (1) TNSN08373A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007120454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200807862B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164133A (zh) * 2013-05-02 2015-12-16 豪夫迈·罗氏有限公司 作为CB2受体激动剂的吡咯并[2,3-d]嘧啶衍生物
CN110062758A (zh) * 2016-12-21 2019-07-26 奇斯药制品公司 作为rho-激酶抑制剂的二环二氢嘧啶-甲酰胺衍生物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201000046A1 (ru) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2009076352A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CR20220661A (es) * 2016-06-23 2023-02-21 Hoffmann La Roche NUEVOS DERIVADOS DE [1,2,3]TRIAZOLO[4,5-D]PIRIMIDINA (Divisional 2018-0615)
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2005049615A1 (en) 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
WO2005061505A1 (en) * 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic imidazolyl pyrimidin-4-one cannabinoid receptor ligands and uses thereof
TW200528455A (en) 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164133A (zh) * 2013-05-02 2015-12-16 豪夫迈·罗氏有限公司 作为CB2受体激动剂的吡咯并[2,3-d]嘧啶衍生物
CN105164133B (zh) * 2013-05-02 2018-02-13 豪夫迈·罗氏有限公司 作为CB2受体激动剂的吡咯并[2,3‑d]嘧啶衍生物
CN110062758A (zh) * 2016-12-21 2019-07-26 奇斯药制品公司 作为rho-激酶抑制剂的二环二氢嘧啶-甲酰胺衍生物
KR20190092439A (ko) * 2016-12-21 2019-08-07 키에시 파르마슈티시 엣스. 피. 에이. Rho-키나아제 억제제로서 바이사이클릭 다이하이드로피리미딘-카복스아마이드 유도체
CN110062758B (zh) * 2016-12-21 2023-01-17 奇斯药制品公司 作为rho-激酶抑制剂的二环二氢嘧啶-甲酰胺衍生物
KR102559612B1 (ko) 2016-12-21 2023-07-26 키에시 파르마슈티시 엣스. 피. 에이. Rho-키나아제 억제제로서 바이사이클릭 다이하이드로피리미딘-카복스아마이드 유도체

Also Published As

Publication number Publication date
RU2008142832A (ru) 2010-05-10
EP1999132A1 (en) 2008-12-10
ES2388881T3 (es) 2012-10-19
JP2009532360A (ja) 2009-09-10
HK1122034A1 (en) 2009-05-08
BRPI0710107A2 (pt) 2011-08-02
JP5253374B2 (ja) 2013-07-31
MX2008012400A (es) 2008-10-10
KR100997601B1 (ko) 2010-11-30
EP1999132B1 (en) 2012-07-18
MA30339B1 (fr) 2009-04-01
PT1999132E (pt) 2012-10-02
KR20080113387A (ko) 2008-12-30
US20090247556A1 (en) 2009-10-01
RU2424242C2 (ru) 2011-07-20
US8722691B2 (en) 2014-05-13
CA2645967C (en) 2011-05-24
CR10309A (es) 2008-12-03
AU2007239033B2 (en) 2011-12-15
TNSN08373A1 (en) 2009-12-29
PL1999132T3 (pl) 2012-12-31
ECSP088852A (es) 2008-11-27
AU2007239033A1 (en) 2007-10-25
WO2007120454A1 (en) 2007-10-25
NO20084489L (no) 2008-12-19
GT200800198A (es) 2009-04-29
ZA200807862B (en) 2009-06-24
CA2645967A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
JP5253374B2 (ja) カンナビノイド受容体1活性の阻害剤としてのアゾロピリミジン類
KR100919524B1 (ko) 칸나비노이드 수용체 1 활성 억제제로서의 화합물 및조성물
JP7566888B2 (ja) アゾール縮合ピリダジン-3(2h)-オン誘導体
CA3189912A1 (en) Bicyclic compounds, compositions and use thereof
HUP0303897A2 (hu) Eljárások p38 kinázzal összafüggő esetek kezelésére, kináz inhibitorokként alkalmazható pirrolotriazin vegyületek és ezeket tartalmazó gyógyszerkészítmények
EP1966215A1 (en) Condensed heterocyclic compounds useful as dpp-iv inhibitors
CN110062758A (zh) 作为rho-激酶抑制剂的二环二氢嘧啶-甲酰胺衍生物
WO2017082759A1 (ru) {3-[(7н-пирролo[2,3-d]пиримидин-4-ил)-азолил]азетидин-3-ил}-ацетонитрилы в качестве ингибиторов янус киназ
HK1122034B (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
EA053259B1 (ru) Конденсированные с азолом производные пиридазин-3(2н)-она

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090610